Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Transfusion Safety Study Group.
The Transfusion Safety Study monitored susceptible persons for human immunodeficiency virus type 1 (HIV-1) infections transmitted by plasma products and blood components. Through December, 1988, 6 subjects without antibody to HIV-1 (anti-HIV-1) became seropositive after receiving dry-heated factor VIII concentrate. The preparations implicated in 3 cases were derived entirely from anti-HIV-1-screened donors. In all instances, HIV-1 infection could be explained by concentrates heated at 60 degrees C for 24-30 h. Limiting consideration to concentrates and components administered after study entry showed that 4 of the seroconversions occurred among 122 subjects given 10 million units of factor VIII concentrates. No seroconversions occurred among 84 subjects given 5 million units of factor IX concentrates, or 83 who received components from over 26,000 unpaid donations. Serologic surveillance of anti-HIV-1-negative subjects provides important information, and should be routine in the management of persons receiving clotting factor concentrates.
Dietrich
S L
SL
University of Southern California, Los Angeles.
Mosley
J W
JW
Lusher
J M
JM
Hilgartner
M W
MW
Operskalski
E A
EA
Habel
L
L
Aledort
L M
LM
Gjerset
G F
GF
Koerper
M A
MA
Lewis
B H
BH
D000163:Acquired Immunodeficiency Syndrome / Q000635:transmission*; D000293:Adolescent; D000328:Adult; D005164:Factor IX / Q000009:adverse effects*; D005169:Factor VIII / Q000009:adverse effects*; D006679:HIV Seropositivity; D015497:HIV-1; D006358:Hot Temperature; D006801:Humans; D008297:Male; D008875:Middle Aged; D065227:Transfusion Reaction
D005169:Factor VIII; D005164:Factor IX